Vladimir Bryntsalov, one of Russia’s richest businessman, and the Belarusian Belbiopharm state concern, may invest up to $120 million in the construction of the largest pharmaceutical plant in Belarus. The new plant is expected to be built in 2015 on the base of a state pharmaceutical company Dialek.
Expected total production capacities of the plant were not disclosed. According to some Belarus media reports, however, the new facility will focus on the production of certain pharmaceutical drugs and antibiotics, which should replace their more expensive imported analogues.
Imports now account for 80% of market
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze